Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1 | $3 | $2 | $2 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $3 | $6 | $0 | $1 |
| Inventory | $2 | $2 | $2 | $4 |
| Other Curr. Assets | $1 | $2 | $2 | $1 |
| Total Curr. Assets | $7 | $12 | $6 | $9 |
| Property Plant & Equip (Net) | $2 | $2 | $3 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $15 | $21 | $19 | $18 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $20 | $26 |
| Total NC Assets | $17 | $24 | $42 | $48 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $24 | $35 | $48 | $57 |
| Liabilities | – | – | – | – |
| Payables | $3 | $1 | $0 | $0 |
| Short-Term Debt | $30 | $29 | $25 | $23 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $10 | $10 | $10 | $7 |
| Other Curr. Liab. | $20 | $22 | $19 | $14 |
| Total Curr. Liab. | $64 | $62 | $54 | $37 |
| LT Debt | $3 | $4 | $6 | $8 |
| Deferred Rev, NC | $0 | $0 | $0 | $10 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $13 | $17 | $22 | $23 |
| Total NC Liab. | $17 | $21 | $28 | $41 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $3 | $3 | $3 | $4 |
| Total Liabilities | $80 | $83 | $82 | $78 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$263 | -$256 | -$252 | -$241 |
| AOCI | -$3 | -$0 | -$3 | -$0 |
| Other Equity | $209 | $208 | $221 | $220 |
| Total Equity | -$56 | -$48 | -$34 | -$21 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $24 | $35 | $48 | $57 |
| Net Debt | $32 | $30 | $29 | $28 |